Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-009207
Date:2023-02-10
Issuer: KINNATE BIOPHARMA INC. (KNTE)
Original Submission Date:

Reporting Person:

KRISHNAMOHAN NEHA
103 MONTGOMERY STREET, SUITE 150
THE PRESIDIO OF SAN FRANCISCO SAN FRANCISCO, CA 94129

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 6.78 2023-02-10 deemed execution date A 215,000 (a) 2033-02-10 common stock 215,000 $6.78 215,000 direct
Footnotes
IDfootnote
f1 one forty-eighth (1/48th) of the total number of shares granted under the option shall vest and become exercisable starting on march 1, 2023 (the "vesting commencement date") and thereafter each month on the same day of the month as the vesting commencement date, until all shares subject to the option have vested on february 1, 2027, subject to the reporting person continuing to be a service provider through each such date.
WhaleWisdom Logo

Elevate your investments